Gold nanoparticles as innovative therapeutics for oral mucositis: A review of current evidence

Choudhury M 1 , Brunton P 2 , Dias G 3 , Schwass D 4 , Meledandri C 5 , Ratnayake J 6 Show all authors , Pletzer D 7 , Tompkins G 6

Affiliations 

  • 1 Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand. Minatichoudhury@imu.edu.my
  • 2 Health Sciences, University of Otago, Dunedin, New Zealand
  • 3 Department of Anatomy, University of Otago, Dunedin, New Zealand
  • 4 Faculty of Dentistry, University of Otago, Dunedin, New Zealand
  • 5 Department of Chemistry, University of Otago, Dunedin, New Zealand
  • 6 Department of Oral Sciences, University of Otago, Dunedin, New Zealand
  • 7 Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand. daniel.pletzer@otago.ac.nz
Drug Deliv Transl Res, 2024 Dec 03.
PMID: 39625578 DOI: 10.1007/s13346-024-01748-x

Abstract

Oral mucositis (OM) remains a debilitating side effect in patients undergoing cancer therapy. DNA damage and oxidative stress generated by radiation and/or chemotherapy activate key inflammatory pathways, ultimately resulting in the destruction of the epithelial barrier, leading to microbial colonization, and ulceration. These ulcerative lesions are often extremely painful, compromising nutrition and oral hygiene, requiring intravenous nutritional support, resulting in longer periods of hospitalization and increased cost. Ulcers often increase the risk of secondary infection, disrupting cancer therapy and patient prognosis. Despite these issues, there is no approved therapy to mitigate OM. Ultrasmall (

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications